CSL Behring's commitment is reflected in our support of programs and activities for patients with rare diseases including bleeding disorders, primary immune deficiencies and Alpha1-proteinase inhibitor deficiencies.
We collaborate with patient advocacy platforms, both disease-specific and umbrella organizations, to promote quality medical care and services and to improve and expand educational and outreach efforts. Through these partnerships we strive to raise public awareness and to enhance appropriate public policies for rare diseases.
We work with government authorities to ensure patients have access to care while also funding medical research.
Finally, as a global company, our public policies extend internationally. Through our membership in the Plasma Protein Therapeutics Association (PPTA), CSL Behring is working with other international trade associations to promote the availability of and access to safe and effective plasma protein therapeutics for all patients.
2/14/2013 5:36 PM